Extension of preclinical research collaboration agreement with a top-10 large pharma company NewsKristin EivindvikJanuary 18, 2018
PCI Biotech announces preliminary outcome of meetings with EMA and FDA for development of fimaporfin in inoperable cholangiocarcinoma NewsKristin EivindvikDecember 20, 2017
PCI Biotech receives US Orphan Drug Designation for fimaporfin in the treatment of bile duct cancer (cholangiocarcinoma) NewsKristin EivindvikOctober 5, 2017
Initial clinical results from Phase I indicate that vaccination with fimaVacc enhances cellular immune responses NewsKristin EivindvikSeptember 12, 2017
Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital NewsKristin EivindvikSeptember 6, 2017
PCI Biotech appoints Dr Hans Olivecrona as Chief Medical Officer NewsKristin EivindvikAugust 23, 2017
Extension of preclinical research collaboration agreement with a top-10 large pharma company NewsKristin EivindvikJuly 10, 2017
